Prudentia Sciences | $7,000,000 | (Jan 10, 2025)
RLTYco | $20,000,000 | (Jan 10, 2025)
A2 Biotherapeutics, Inc.
United States
- Agoura Hills, CA
- 10/01/2025
- Series C
- $80,000,000
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed.
The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.
- Industry Biotechnology Research
- Website https://www.a2bio.com/
- LinkedIn https://www.linkedin.com/company/a2-biotherapeutics/
Related People
Jim RobinsonFounder
United States -
Agoura Hills, California
With over 30 years of experience in the life sciences industry, I have a passion for developing and launching innovative products that address unmet medical needs and improve the quality of life for patients and their families. As the CEO, President and Board Member of A2 Biotherapeutics, I lead a team of talented and dedicated professionals who are advancing a novel platform for generating cell therapies for cancers.
In addition to my role at A2 Biotherapeutics, I serve on the Board of Directors of two other biopharmaceutical companies, Eledon Pharmaceuticals and UroGen Pharma, that are focused on developing and commercializing therapies for immunological and urological diseases, respectively. I serve on the Board of Directors of Petauri Health which is dedicated to improving access to life-changing healthcare innovations.
I leverage my extensive global experience and expertise in these areas to provide strategic guidance and support to these organizations as they pursue their mission and vision. I am honored and excited to be part of the dynamic biopharma community and to contribute to the advancement of science and medicine.
Air | $35,000,000 | (Jan 10, 2025)
Biosphere | $8,800,000 | (Jan 10, 2025)
RyboDyn Inc. | $4,000,000 | (Jan 10, 2025)
Abstract(US) | $4,800,000 | (Jan 10, 2025)
PrettyDamnQuick | $25,000,000 | (Jan 10, 2025)
Oxford Cancer Analytics | $11,000,000 | (Jan 10, 2025)
UNLISTED | $2,250,000 | (Jan 9, 2025)
Zeto / Rapid Full-Montage EEG | $31,000,000 | (Jan 9, 2025)
Red Rover Health, Inc. | $4,000,000 | (Jan 9, 2025)